In a conversation with Bernd grobe a couple of interesting issues/situations emerged.
At present Bernd has signed up a total of 5 companies for the cancer audit in Europe. All are clients of the Tandem Cancer Audit in the U.S. they are:.
GSK Boehringer-Ingelheim, Amgen, Bayer, J&J.
He has targeted a few more. At the top of the list are Pharmacia and Lilly. Again, these are clients of ours in the states.
His "breakeven" appears to be around 7/8 clients so he seems to be almost there of course to be achieved "breakeven" would have to be "full clients", which I believe these are.
A number of the companies are on his radar screen he specifically mentioned Bristol Meyers, Schering. Roche & Novartis.
Others talked about were Aventis Astra Zeneca Merck, Wyeth and Pfizer. The latter are lower on the list. All the above are present clients of the U.S. Tandem Cancer Audit.
The recent (past year) success of he I+G Cancer Patient Monitor (CPM) appears to trace to a couple of factors.
The audit was expanded to include many more records within & across the five (5) European countries.
The fact that the IMS buyout of Medicare Audits and their apparent inability to deliver a quality product left a lot of dissatisfied companies. These were ripe for I+G to pick up and they did further, ISIS does not as yet appear to represent a viable alternative.
I+G will probably continue to pick up clients given the preceding situation.
We also discussed Japan from the standpoint of servicing Japanese company cancer data needs in the U.S. and /or Europe. As you know I look at this as an opportunity for Tandem as well, and so does Bernd for I+G.
It's my feeling based on what I have heard in the market & what has been demonstrated by the I+G success to date that the CPM represents the best alternative in Europe for the Cancer Audit Database.
I+G has made it more robust, charged a fair price and have a product that is most compatible to the Tandem Cancer Audit.